Evidence map›Paper›PMID 34498712›Full record

ArticleMolecular medicine reports2021

miR221 regulates TGF-β1-induced HSC activation through inhibiting autophagy by directly targeting LAMP2.

Ran Cheng, Hao Xu, Yang Hong

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ran ChengThe First Department of Hepatobiliary Surgery, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China.
Hao XuMedical Insurance Office, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.
Yang HongDepartment of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.
Hebei Medical University · CNTangshan Gongren Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver fibrosis is a serious threat to human life and health. Activated hepatic stellate cells (HSCs) play a key role in the occurrence and development of liver fibrosis. Studies have reported that microRNAs (miRNAs/miRs) are involved in the pathological process of fibrosis, as well as its relevance in clinical diagnosis. However, the role of miR221 in hepatic fibrosis remains controversial. Remarkably, transforming growth factor‑β (TGF‑β1) caused HSC dysfunction in autophagic activation, characterized by an increase in P62 aggregation and LC3II expression. The present study aimed to determine whether autophagy regulates hepatic fibrosis by mediating HSC activation and explore the potential targets leading to the sequence of events associated with miR221. The expression of miR221 was quantified in a liver fibrosis model

Indexed as

AnimalsApoptosisAutophagyBiomarkersCell ProliferationCells, CulturedHepatic Stellate CellsLiver CirrhosisLysosomal-Associated Membrane Protein 2MaleMiceMice, Inbred C57BLMicroRNAsTransforming Growth Factor beta1BiomarkersLysosomal-Associated Membrane Protein 2MicroRNAsMIRN221 microRNA, mouseTgfb1 protein, mouseTransforming Growth Factor beta1liver fibrosislysosome-associated membrane glycoprotein 2microRNA221transforming growth factor-β

Identifiers

PMID34498712
PMCPMC8436230
OpenAlexW3197108559

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.